(Q54105461)

English

Ovarian cancer

scholarly article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Ovarian cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

1 reference

based on heuristic

inferred from title

Gordon C. Jayson

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

author name string

Elise C Kohn

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Henry C Kitchener

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Jonathan A Ledermann

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

language of work or name

0 references

publication date

21 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

384

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

9951

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

1376-1388

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Recent progress in the diagnosis and treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro fertilization is associated with an increased risk of borderline ovarian tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

ARID1A mutations in endometriosis-associated ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Failure to demonstrate human papillomavirus DNA in epithelial ovarian cancer by general primer PCR

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective study of talc use and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian cancer and smoking: individual participant meta-analysis including 28,114 women with ovarian cancer from 51 epidemiological studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hereditary gynaecological malignancies: advances in screening and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining the cut point between low-grade and high-grade ovarian serous carcinomas: a clinicopathologic and molecular genetic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of symptoms of ovarian cancer in women presenting to primary care clinics

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifying symptoms of ovarian cancer: a qualitative and quantitative study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Staging classification for cancer of the ovary, fallopian tube, and peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Secondary surgical cytoreduction for advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian cancer surgical resectability: relative impact of disease, patient status, and surgeon

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Second look laparotomy and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Surgical staging and treatment of early ovarian cancer: long-term analysis from a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label tr

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Patient reported outcomes of a randomized, placebo-controlled trial of bevacizumab in the front-line treatment of ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting MET in cancer: rationale and progress

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Hormone replacement therapy and survival after surgery for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Estrogen replacement therapy for ovarian carcinoma survivors: A randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Paraneoplastic thrombocytosis in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tube

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Doctor, does this mean I'm going to starve to death?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for ovarian cancer: a pilot randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of Screening on Ovarian Cancer Mortality

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2813%2962146-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(13)62146-7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

release_irgpuih6zrfghfkkcqoiwvk3ku

1 reference

https://api.fatcat.wiki/v0/release/irgpuih6zrfghfkkcqoiwvk3ku

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24767708%20AND%20SRC:MED&resulttype=core&format=json

16 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54105461&oldid=1839236249"